Scalper1 News
Specialty drugmaker Jazz Pharmaceuticals (JAZZ) hit another new high in the stock market today as the company prepared to deliver its Q4 earnings report after the market close on Tuesday. Analysts polled by Thomson Reuters estimate that the quarter’s profit totaled $1.78 a share, up 16% from the year-earlier quarter. Sales were estimated to rise 30% to $238 million. The outlook for the coming year will likely be of greatest interest to Wall Scalper1 News
Scalper1 News